Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression

Neuroscience Letters

Volumn 597, Issue , 2015, Pages 121-126

  Mendez David, Indira ^a   Tritschler, Laurent ^a   El Ali, Zeina ^a   Damiens, Marie Hélène ^a   Pallardy, Marc ^a   David, Denis J ^a   Kerdine Römer, Saadia ^a   Gardier, Alain M ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Animal model of anxiety depression; Antidepressant; BDNF; Nrf2 pathway

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; FLUOXETINE; TRANSCRIPTION FACTOR NRF2; ANTIDEPRESSANT AGENT; NFE2L2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DEPRESSION; HIPPOCAMPUS; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; CORTICOSTERONE; DEPRESSION; FLUOXETINE; HIPPOCAMPUS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION;

EID: 84929657641     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.04.036     Document Type: Article

References (34)

1. Trivedi M.H., Fava M., Marangell L.B., Osser D.N., Shelton R.C. Use of treatment algorithms for depression. Prim. Care Compan. J. Clin. Psychiatry 2006, 8:291-298.
2. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
3. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro. Endocrinol. Lett. 2008, 29:287-291.
4. McNally L., Bhagwagar Z., Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr. 2008, 13:501-510.
5. Abdel-Wahab B.A., Salama R.H. Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol. Biochem. Behav. 2011, 100:59-65.
6. Behr G.A., Moreira J.C., Frey B.N. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid. Med. Cell. Longev. 2012, 2012:609421.
7. Lee S.Y., Lee S.J., Han C., Patkar A.A., Masand P.S., Pae C.U. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:224-235.
8. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53:401-426.
9. Martin-de-Saavedra M.D., Budni J., Cunha M.P., Gomez-Rangel V., Lorrio S., Del Barrio L., Lastres-Becker I., Parada E., Tordera R.M., Rodrigues A.L., Cuadrado A., Lopez M.G. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 2013, 38:2010-2022.
10. Lee J.M., Li J., Johnson D.A., Stein T.D., Kraft A.D., Calkins M.J., Jakel R.J., Johnson J.A. Nrf2, a multi-organ protector?. FASEB J. 2005, 19:1061-1066.
11. Bataille A.M., Manautou J.E. Nrf2: a potential target for new therapeutics in liver disease. Clin. Pharmacol. Ther. 2012, 92:340-348.
12. Ma Q., Battelli L., Hubbs A.F. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am. J. Pathol. 2006, 168:1960-1974.
13. Pae C.U., Yoon S.J., Patkar A.A., Kim J.J., Lee C., Paik I.H. Quinone oxidoreductase (NQO1) gene polymorphism may not confer a susceptibility to mood disorders. Psychiatry Res. 2007, 153:83-86.
14. Berk M., Johansson S., Wray N.R., Williams L., Olsson C., Haavik J., Bjerkeset O. Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT. J. Affect. Disord. 2011, 131:207-213.
15. David D.J., Samuels B.A., Rainer Q., Wang J.W., Marsteller D., Mendez I., Drew M., Craig D.A., Guiard B.P., Guilloux J.P., Artymyshyn R.P., Gardier A.M., Gerald C., Antonijevic I.A., Leonardo E.D., Hen R. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62:479-493.
16. Mendez-David I., David D.J., Darcet F., Wu M.V., Kerdine-Romer S., Gardier A.M., Hen R. Rapid anxiolytic effects of a 5-HT(4) receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology 2014, 39:1366-1378.
17. Castren E. Neurotrophins and psychiatric disorders. Handb. Exp. Pharmacol. 2014, 220:461-479.
18. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., Oyake T., Hayashi N., Satoh K., Hatayama I., Yamamoto M., Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 1997, 236:313-322.
19. Rainer Q., Nguyen H.T., Quesseveur G., Gardier A.M., David D.J., Guiard B.P. Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Mol. Pharmacol. 2012, 81:106-112.
20. Guilloux J.P., Seney M., Edgar N., Sibille E. Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex. J. Neurosci. Methods 2011, 197:21-31.
21. Mendez-David I., El-Ali Z., Hen R., Falissard B., Corruble E., Gardier A.M., Kerdine-Romer S., David D.J. A method for biomarker measurements in peripheral blood mononuclear cells isolated from anxious and depressed mice: beta-arrestin 1 protein levels in depression and treatment. Front Pharmacol. 2013, 4:124.
22. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:664-675.
23. Maes M., Mihaylova I., Kubera M., Ringel K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36:169-175.
24. Innamorato N.G., Rojo A.I., Garcia-Yague A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 2008, 181:680-689.
25. Lukic I., Mitic M., Djordjevic J., Tatalovic N., Bozovic N., Soldatovic I., Mihaljevic M., Pavlovic Z., Radojcic M.B., Maric N.P., Adzic M. Lymphocyte levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of pro-oxidative state in depressive patients. Neuropsychobiology 2014, 70:1-9.
26. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
27. Patricio P., Mateus-Pinheiro A., Irmler M., Alves N.D., Machado-Santos A.R., Morais M., Correia J.S., Korostynski M., Piechota M., Stoffel R., Beckers J., Bessa J.M., Almeida O.F., Sousa N., Pinto L. Differential and converging molecular mechanisms of antidepressants' action in the hippocampal dentate gyrus. Neuropsychopharmacology 2015, 40:338-349.
28. Alam J., Cook J.L. How many transcription factors does it take to turn on the heme oxygenase-1 gene?. Am. J. Respir. Cell Mol. Biol. 2007, 36:166-174.
29. Ishii T., Itoh K., Ruiz E., Leake D.S., Unoki H., Yamamoto M., Mann G.E. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res. 2004, 94:609-616.
30. Scapagnini G., Colombrita C., Amadio M., D'Agata V., Arcelli E., Sapienza M., Quattrone A., Calabrese V. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid. Redox Signal. 2006, 8:395-403.
31. Bocchio-Chiavetto L., Bagnardi V., Zanardini R., Molteni R., Nielsen M.G., Placentino A., Giovannini C., Rillosi L., Ventriglia M., Riva M.A., Gennarelli M. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J. Biol. Psychiatry 2010, 11:763-773.
32. Kurita M., Nishino S., Kato M., Numata Y., Sato T. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS One 2012, 7:e39212.
33. Karkkainen V., Pomeshchik Y., Savchenko E., Dhungana H., Kurronen A., Lehtonen S., Naumenko N., Tavi P., Levonen A.L., Yamamoto M., Malm T., Magga J., Kanninen K.M., Koistinaho J. Nrf2 regulates neurogenesis and protects neural progenitor cells against Abeta toxicity. Stem Cells 2014, 32:1904-1916.
34. Qi D., Ouyang C., Wang Y., Zhang S., Ma X., Song Y., Yu H., Tang J., Fu W., Sheng L., Yang L., Wang M., Zhang W., Miao L., Li T., Huang X., Dong H. HO-1 attenuates hippocampal neurons injury via the activation of BDNF-TrkB-PI3K/Akt signaling pathway in stroke. Brain Res. 2014, 1577:69-76.